199 related articles for article (PubMed ID: 20952418)
21. CYP2B6 G516T polymorphism but not rifampin coadministration influences steady-state pharmacokinetics of efavirenz in human immunodeficiency virus-infected patients in South India.
Ramachandran G; Hemanth Kumar AK; Rajasekaran S; Kumar P; Ramesh K; Anitha S; Narendran G; Menon P; Gomathi C; Swaminathan S
Antimicrob Agents Chemother; 2009 Mar; 53(3):863-8. PubMed ID: 19124658
[TBL] [Abstract][Full Text] [Related]
22. Pharmacogenetic-based efavirenz dose modification: suggestions for an African population and the different CYP2B6 genotypes.
Mukonzo JK; Owen JS; Ogwal-Okeng J; Kuteesa RB; Nanzigu S; Sewankambo N; Thabane L; Gustafsson LL; Ross C; Aklillu E
PLoS One; 2014; 9(1):e86919. PubMed ID: 24497997
[TBL] [Abstract][Full Text] [Related]
23. Effect of CYP2B6 Gene Polymorphisms on Efavirenz Plasma Concentrations in Chinese Patients with HIV Infection.
Meng X; Yin K; Wang J; Dong P; Liu L; Shen Y; Shen L; Ma Q; Lu H; Cai W
PLoS One; 2015; 10(6):e0130583. PubMed ID: 26107645
[TBL] [Abstract][Full Text] [Related]
24. Cytochrome P450 2B6 (CYP2B6) and constitutive androstane receptor (CAR) polymorphisms are associated with early discontinuation of efavirenz-containing regimens.
Wyen C; Hendra H; Siccardi M; Platten M; Jaeger H; Harrer T; Esser S; Bogner JR; Brockmeyer NH; Bieniek B; Rockstroh J; Hoffmann C; Stoehr A; Michalik C; Dlugay V; Jetter A; Knechten H; Klinker H; Skaletz-Rorowski A; Fätkenheuer G; Egan D; Back DJ; Owen A;
J Antimicrob Chemother; 2011 Sep; 66(9):2092-8. PubMed ID: 21715435
[TBL] [Abstract][Full Text] [Related]
25. Identification of a novel specific CYP2B6 allele in Africans causing impaired metabolism of the HIV drug efavirenz.
Wang J; Sönnerborg A; Rane A; Josephson F; Lundgren S; Ståhle L; Ingelman-Sundberg M
Pharmacogenet Genomics; 2006 Mar; 16(3):191-8. PubMed ID: 16495778
[TBL] [Abstract][Full Text] [Related]
26. Plasma efavirenz concentrations and the association with CYP2B6-516G >T polymorphism in HIV-infected Thai children.
Puthanakit T; Tanpaiboon P; Aurpibul L; Cressey TR; Sirisanthana V
Antivir Ther; 2009; 14(3):315-20. PubMed ID: 19474465
[TBL] [Abstract][Full Text] [Related]
27. Pharmacokinetic and Pharmacodynamic Comparison of Once-Daily Efavirenz (400 mg vs. 600 mg) in Treatment-Naïve HIV-Infected Patients: Results of the ENCORE1 Study.
Dickinson L; Amin J; Else L; Boffito M; Egan D; Owen A; Khoo S; Back D; Orrell C; Clarke A; Losso M; Phanuphak P; Carey D; Cooper DA; Emery S; Puls R;
Clin Pharmacol Ther; 2015 Oct; 98(4):406-16. PubMed ID: 26044067
[TBL] [Abstract][Full Text] [Related]
28. Pharmacogenetics of plasma efavirenz exposure in HIV-infected adults and children in South Africa.
Sinxadi PZ; Leger PD; McIlleron HM; Smith PJ; Dave JA; Levitt NS; Maartens G; Haas DW
Br J Clin Pharmacol; 2015 Jul; 80(1):146-56. PubMed ID: 25611810
[TBL] [Abstract][Full Text] [Related]
29. Secondary metabolism pathway polymorphisms and plasma efavirenz concentrations in HIV-infected adults with CYP2B6 slow metabolizer genotypes.
Haas DW; Kwara A; Richardson DM; Baker P; Papageorgiou I; Acosta EP; Morse GD; Court MH
J Antimicrob Chemother; 2014 Aug; 69(8):2175-82. PubMed ID: 24729586
[TBL] [Abstract][Full Text] [Related]
30. Genome-wide association study of plasma efavirenz pharmacokinetics in AIDS Clinical Trials Group protocols implicates several CYP2B6 variants.
Holzinger ER; Grady B; Ritchie MD; Ribaudo HJ; Acosta EP; Morse GD; Gulick RM; Robbins GK; Clifford DB; Daar ES; McLaren P; Haas DW
Pharmacogenet Genomics; 2012 Dec; 22(12):858-67. PubMed ID: 23080225
[TBL] [Abstract][Full Text] [Related]
31. Successful efavirenz dose reduction in HIV type 1-infected individuals with cytochrome P450 2B6 *6 and *26.
Gatanaga H; Hayashida T; Tsuchiya K; Yoshino M; Kuwahara T; Tsukada H; Fujimoto K; Sato I; Ueda M; Horiba M; Hamaguchi M; Yamamoto M; Takata N; Kimura A; Koike T; Gejyo F; Matsushita S; Shirasaka T; Kimura S; Oka S
Clin Infect Dis; 2007 Nov; 45(9):1230-7. PubMed ID: 17918089
[TBL] [Abstract][Full Text] [Related]
32. Genetic variability of CYP2B6 in populations of African and Asian origin: allele frequencies, novel functional variants, and possible implications for anti-HIV therapy with efavirenz.
Klein K; Lang T; Saussele T; Barbosa-Sicard E; Schunck WH; Eichelbaum M; Schwab M; Zanger UM
Pharmacogenet Genomics; 2005 Dec; 15(12):861-73. PubMed ID: 16272958
[TBL] [Abstract][Full Text] [Related]
33. Influence of efavirenz pharmacokinetics and pharmacogenetics on neuropsychological disorders in Ugandan HIV-positive patients with or without tuberculosis: a prospective cohort study.
Mukonzo JK; Okwera A; Nakasujja N; Luzze H; Sebuwufu D; Ogwal-Okeng J; Waako P; Gustafsson LL; Aklillu E
BMC Infect Dis; 2013 Jun; 13():261. PubMed ID: 23734829
[TBL] [Abstract][Full Text] [Related]
34. Importance of ethnicity, CYP2B6 and ABCB1 genotype for efavirenz pharmacokinetics and treatment outcomes: a parallel-group prospective cohort study in two sub-Saharan Africa populations.
Ngaimisi E; Habtewold A; Minzi O; Makonnen E; Mugusi S; Amogne W; Yimer G; Riedel KD; Janabi M; Aderaye G; Mugusi F; Bertilsson L; Aklillu E; Burhenne J
PLoS One; 2013; 8(7):e67946. PubMed ID: 23861838
[TBL] [Abstract][Full Text] [Related]
35. Correlation of CYP2B6-516G > T Polymorphism with Plasma Efavirenz Concentration and Depression in HIV-Infected Adults in Northern Thailand.
Aurpibul L; Chotirosniramit N; Sugandhavesa P; Kosashunhanan N; Thetket S; Supindham T; Piyamongkol W; Supparatpinyo K
Curr HIV Res; 2012 Dec; 10(8):653-60. PubMed ID: 22950382
[TBL] [Abstract][Full Text] [Related]
36. CYP2B6 983T>C polymorphism is prevalent in West Africa but absent in Papua New Guinea: implications for HIV/AIDS treatment.
Mehlotra RK; Bockarie MJ; Zimmerman PA
Br J Clin Pharmacol; 2007 Sep; 64(3):391-5. PubMed ID: 17391322
[TBL] [Abstract][Full Text] [Related]
37. Mid-dosing interval efavirenz plasma concentrations in HIV-1-infected children in Rwanda: treatment efficacy, tolerability, adherence, and the influence of CYP2B6 polymorphisms.
Mutwa PR; Fillekes Q; Malgaz M; Tuyishimire D; Kraats Rv; Boer KR; Burger DM; van Schaik RH; Muganga N; Geelen SP
J Acquir Immune Defic Syndr; 2012 Aug; 60(4):400-4. PubMed ID: 22481606
[TBL] [Abstract][Full Text] [Related]
38. Worldwide variation in human drug-metabolism enzyme genes CYP2B6 and UGT2B7: implications for HIV/AIDS treatment.
Li J; Menard V; Benish RL; Jurevic RJ; Guillemette C; Stoneking M; Zimmerman PA; Mehlotra RK
Pharmacogenomics; 2012 Apr; 13(5):555-70. PubMed ID: 22462748
[TBL] [Abstract][Full Text] [Related]
39. The impact of genetic polymorphisms on the pharmacokinetics of efavirenz in African children.
Bienczak A; Cook A; Wiesner L; Olagunju A; Mulenga V; Kityo C; Kekitiinwa A; Owen A; Walker AS; Gibb DM; McIlleron H; Burger D; Denti P
Br J Clin Pharmacol; 2016 Jul; 82(1):185-98. PubMed ID: 26991336
[TBL] [Abstract][Full Text] [Related]
40. CYP2B6 polymorphism and nonnucleoside reverse transcriptase inhibitor plasma concentrations in Chinese HIV-infected patients.
Chen J; Sun J; Ma Q; Yao Y; Wang Z; Zhang L; Li L; Sun F; Lu H
Ther Drug Monit; 2010 Oct; 32(5):573-8. PubMed ID: 20625352
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
